人乳头瘤病毒（HPV）和 Epstein-Barr 病毒（EBV）与泰国阴茎癌的关系。

Human papillomavirus (HPV) and Epstein-Barr virus (EBV) in Penile Cancer in Thailand.

机构信息

Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

出版信息

Asian Pac J Cancer Prev. 2024 Oct 1;25(10):3543-3549. doi: 10.31557/APJCP.2024.25.10.3543.

DOI:10.31557/APJCP.2024.25.10.3543

PMID:39471020

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11711368/

Abstract

BACKGROUND

Human papillomavirus (HPV) and Epstein-Barr virus (EBV) are important etiological factors for several cancers. This study aimed to determine the prevalence of HPV and EBV infection in penile cancer.

METHODS

Forty-three formalin-fixed paraffin-embedded penile cancer tissue samples were analyzed for the HPV-induced p16INK4A protein by immunohistochemistry and Epstein-Barr encoding region in situ hybridization. Demographic data and overall survival were analyzed.

RESULTS

The median age of patients was 59 years, ranging from 23 to 91 years old. Most of the tumors (86%) were located at the tip of the penis. HPV infection was positive in 12/43 (27.9%) patients. EBV infection was observed in 2/43 (4.6%) of cases and there was no co-infection detected in this cohort. Patients who had p16INK4A overexpression had a trend toward longer survival compared to those without; the median survival time of 104.4 vs 89 months, the hazard ratio of 0.48 (95% CI: 0.16-1.42, p = 0.173).

CONCLUSIONS

One-third of penile cancer patients were positive for HPV-induced p16INK4A expression and there was a trend toward better survival in HPV-positive patients. EBV infection was infrequent in penile cancer in Thailand.

摘要

背景

人乳头瘤病毒（HPV）和 Epstein-Barr 病毒（EBV）是多种癌症的重要病因。本研究旨在确定阴茎癌中 HPV 和 EBV 感染的流行情况。

方法

对 43 例福尔马林固定石蜡包埋的阴茎癌组织样本进行 HPV 诱导的 p16INK4A 蛋白免疫组织化学和 EBV 编码区原位杂交分析。分析了人口统计学数据和总生存率。

结果

患者的中位年龄为 59 岁，范围为 23 至 91 岁。大多数肿瘤（86%）位于阴茎尖端。43 例患者中有 12 例（27.9%）HPV 感染阳性。2 例（4.6%）病例中观察到 EBV 感染，本队列未检测到合并感染。与无 p16INK4A 过表达的患者相比，p16INK4A 过表达的患者有更长的生存趋势；中位生存时间分别为 104.4 个月和 89 个月，风险比为 0.48（95%CI：0.16-1.42，p=0.173）。